Health Economical Aspects of Alzheimer Disease and its Treatment
PsychogeriatricsPublished 1 September 2001Open access
Anders Wimo, Bengt Winblad
Citations21
SJR quartileQ2
SJR score0.68
SNIP0.64
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
In particular, aspects of quality of life among patients and caregivers, long term treatment effects and informal care should be the focus for methodological development.
Abstract
Abstract: The health economics of Alzheimer disease (AD) is in a premature state, and there is a great need for methodological improvement. The scientific database is small although rapidly expanding. There is also a great interest in the pharmacoeconomics of AD amongst the drug authorities in different countries and in the pharmaceutical companies who are engaged in AD research, illustrating that it is a hot topic. In particular, aspects of quality of life among patients and caregivers, long term treatment effects and informal care should be the focus for methodological development.
Keywords
Economics, Econometrics and Finance
New England Journal of MedicineA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
2,371 Citations1997Mary Sano, Christopher Ernesto +10 more
In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
American Journal of Public HealthThe US economic and social costs of Alzheimer's disease revisited.
594 Citations1994Rebecka Ernst, Joel W. Hay
New national prevalence estimates of the economic and social costs of Alzheimer's disease are presented and the estimated discounted present values of the direct and total costs of all current and future generations of Alzheimer’s patients are $536 billion and $1.75 trillion.
NeurologyLong-term tacrine (Cognex) treatment
296 Citations1996David S. Knopman, Lon S. Schneider +5 more
Treatment with tacrine at doses > 80 mg/d was associated with a reduced likelihood of NHP, demonstrating that tacrine's 30-week effects on cognitive function and clinicians' global ratings may generalize to effects on a major milestone of AD.
NeurologyCost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease
240 Citations1999Peter J. Neumann, Richard C. Hermann +8 more
The results of the cost-effectiveness model presented here suggest that donepezil may be cost-effective but additional controlled data on long-term drug efficacy are needed.
PubMedNet economic costs of dementia in Canada.
179 Citations1994Truls Østbye, E. Crosse
The annual net economic cost of dementia in Canada is at least $3.9 billion, and the most significant component of the total cost was for care in long-term care institutions and for assistance with ADLs by professionals, family and friends in the community.
Archives of NeurologyCognitive Function and the Costs of Alzheimer Disease
172 Citations1997Richard L. Ernst
Large savings in the costs of caring for moderately to severely demented home-dwelling patients with AD may be achievable from disease interventions that have minor effects on patients' cognitive status.
Journal of the American Geriatrics SocietyEconomic Evaluation of Donepezil for the Treatment of Alzheimer's Disease in Canada
125 Citations1999Bernie J. OʼBrien, Ron Goeree +5 more
The cost‐effectiveness of donepezil 5 mg daily as an adjunct to usual care in the management of persons with mild‐to‐moderate AD defined as a Mini‐Mental Health State Examination (MMSE) score in the range 10 to 26 is estimated.
Clinical TherapeuticsThe cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: A Markov model
96 Citations1999Linus Jönsson, Peter Lindgren +3 more
Donepezil had superior cost-effectiveness compared with no treatment, and both models demonstrated various degrees of cost savings and improved effectiveness, as measured by increased time in nonsevere disease states.
Clinical TherapeuticsAn economic evaluation of donepezil in the treatment of Alzheimer's disease
95 Citations1998Gary W. Small, Jane A. Donohue +1 more
Although the patients receivingdonepezil had greater expenditures for prescription drugs, these costs were offset by a slower rate of institutionalization, and the cost of receiving donepezil treatment for 6 months did not result in a significantly higher per-patient mean direct cost.
International Journal of Geriatric PsychiatryPharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil
92 Citations1998Alan Stewart, R Phillips +1 more
Expected direct costs of care over 5 years after diagnosis of Alzheimer's disease (AD) for patients aged 75 years and over at diagnosis and a Markov model showed that donepezil patients spent less time in the state of severe dementia, where Costs of care are higher.
PubMedPrinciples underlying selection of outcomes in Alzheimer disease research.
91 Citations1997Richard H. Fortinsky, Helen P. Hazuda +5 more
This first Italian study on primary data highlights the impressive economic burden of AD on families and shows that AD puts many Italian families at great financial risk.
The British Journal of PsychiatryThe Prevalence and Costs of Psychiatric Disorders and Learning Disabilities
75 Citations1995Kirsteen Smith, Ajit N. Shah +2 more
The findings show that learning disability, schizophrenia and neurotic conditions (including depression) are major burdens on the National Health Service; senile dementia and depression in older people impact largely on local authority social services.
PharmacoEconomicsEstimating Long Term Cost Savings from Treatment of Alzheimer??s Disease
75 Citations1999Paul Fenn, Alastair Gray
The model is a possible approach for estimating cost savings with treatment of AD, given the lack of long term data on resource use and drug efficacy, and should be used when extrapolating the results beyond the original study parameters.
Dementia and Geriatric Cognitive DisordersThe Cost of Dementia in Denmark: The Odense Study
63 Citations1999Christian Kronborg Andersen, Jes Søgaard +8 more
In a population-based study of dementia, the cost of care for 245 demented elderly and 490 controls matched by age and gender was estimated and except for very mild dementia the cost did not differ between elderly who suffer from Alzheimer’s disease and those with other types of dementia.
Clinical TherapeuticsThe economic impact of tacrine in the treatment of Alzheimer's disease
57 Citations1997Curtis J. Henke, Michael J. Burchmore
The use of tacrine for patients with mild-to-moderate Alzheimer's disease reduces the costs of medical and social services required for care, and it increases functioning and delays nursing home placement for up to 433 days.
International Journal of Geriatric PsychiatryCost of illness due to dementia in Sweden
54 Citations1997Anders Wimo, Göran Karlsson +3 more
The gross cost of illness due to dementia was estimated to be SEK30.7 billion in 1991 while the net cost was estimated in 1991, and the sensitivity analysis showed a variation between SEK20 billion and SEK36billion in 1991.
PubMedTreatment of Alzheimer disease with tacrine: a cost-analysis model.
42 Citations1997Anders Wimo, G Karlsson +2 more
The main conclusion is that tacrine, according to the model, has beneficial but modest effects on the costs of Alzheimer disease in Sweden.
PubMedPotential effect of tacrine on expenditures for Alzheimer's disease.
36 Citations1994DP Lubeck, Mazonson Pd +1 more
Tacrine therapy could generate savings up to 17% of the current costs of AD, or a total of $3.6 billion annually for the estimated 1.6 million persons with mild-to-moderate AD.
Alzheimer Disease & Associated DisordersFirst International Pharmacoeconomic Conference on Alzheimerʼs Disease: Report and Summary
32 Citations1998Peter J. Whitehouse, Bengt Winblad +19 more
The First International Pharmacoeconomic Conference on Alzheimer's Disease (AD) was held in Amsterdam in July 1998 and a range of exciting futures were predicted, although common themes that arose when considering barriers to achieving these futures included cost, education, political will, confidentiality, privacy, and ethics.
Alzheimer Disease & Associated DisordersSecond International Pharmacoeconomic Conference on Alzheimer's Disease
27 Citations2000Linus Jönsson, Bengt Jönsson +3 more
The contingent valuation method is an alternative way of valuing informal care that so far has not been used in the field of dementia, and it has a large impact on the results of pharmacoeconomic evaluations.
PubMedMinimizing bias in industry-sponsored outcomes research.
25 Citations1994Freeman Ra
Industry-sponsored research is receiving a considerable amount of attention from public policy makers and private sector decision makers on issues such as bias, objectivity, ethical conduct, and methodological standards.
Clinical TherapeuticsEconomic impact of introducing propentofylline for the treatment of dementia in Sweden
18 Citations1998Anders Wimo, Elke Witthaus +2 more
The clinical effects of propentofylline translate into meaningful economic effects and the inclusion of a broader range of outcomes may increase these savings.